Abstract
A patient with acute myelogenous leukemia developed prolonged bone marrow failure along with the monosomy 7 chromosome abnormality.The patient had undergone bone marrow transplantation with CD34+ selection following induction failure. However, she then suffered engraftment failure and long-term pancytopenia. Her white blood cell count gradually increased with supportive therapy including granulocyte colony-stimulating factor (G-CSF), and chromosomal analysis of bone marrow cells revealed an abnormal karyotype.Thirty months after the bone marrow transplantation we observed monosomy 7 together with the existing chromosomal abnormality in the patient’s bone marrow cells. It has been reported that some patients with idiopathic and posthepatitis aplastic anemia develop clonal disorders such as myelodysplastic syndrome/acute myelogenous leukemia with monosomy 7. The findings in our case suggest that the appearance of monosomy 7 in patients with aplastic anemia may be caused by prolonged low-level hematopoiesis, with or without G-CSF stimulation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
The Japanese Society of Pediatric Hematology, Bone Marrow Transplantation Committee. National registry of bone marrow transplantation in children—1997.Jpn J Pediatr Hematol. 1998;12:93–105.
Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylpred-nisolone with or without cyclosporin. The German Aplastic Anemia Study Group.N Engl J Med. 1991;324:1297–1304.
Bacigalupo A, Chaple M, Hows J, et al. Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party.Br J Haematol. 1993;83:145–151.
Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immuno-suppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia.Blood. 1995;85:3058–3065.
Bacigalupo A, Broccia G, Corda G, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA working party.Blood. 1995;85:1348–1353.
Tichelli A, Gratwohl A, Wursch A, Nissen C, Speck B. Late haematological complications in severe aplastic anemia.Br J Haematol. 1988;69:413–418.
de Planque M, Bacigalupo A, Wursch A, et al. Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT).Br J Haematol. 1989;73:121–126.
Socie G, Henry AM, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.N Engl J Med. 1993;329:1152–1157.
Kojima S, Tsuchida M, Matsuyama T. Myelodysplasia and leukemia after treatment of aplastic anemia with G-CSF.N Engl J Med. 1992;326:1294–1295.
Imashuku S, Hibi S, Kataoka MY, et al. Myelodysplasia and acute myeloid leukaemia in cases of aplastic anemia and congenital neutropenia following G-CSF administration.Br J Haematol. 1995;89:188–190.
Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia.Blood. 1997;90:1009–1013.
Ohsaka A, Sugahara Y, Imai Y, Kikuchi M. Evolution of severe aplastic anemia to myelodysplasia with monosomy 7 following granulocyte colony-stimulating factor, erythropoietin and high-dose methylprednisolone combination therapy.Intern Med. 1995;34:892–895.
Imashuku S, Hibi S, Nakajima F, et al. A review of 125 cases to determine the risk of myelodysplasia and leukemia in pediatric neutropenic patients after treatment with recombinant human granulocyte colony-stimulating factor.Blood. 1994;84:2380–2381.
Hotta T. Clonality in hematopoietic disorders.Int J Hematol. 1997;66:403–412.
Sont JK, van Stiphout WA, Noordijk EM, et al. Increased risk of second cancers in managing Hodgkin’s disease: the 20-year Leiden experience.Ann Hematol. 1992;65:213–218.
Travis LB, Curtis RE, Boice JD, et al. Second cancers following non-Hodgkin’s lymphoma.Cancer. 1991;67:2002–2009.
Abrahamsen JF, Andersen A, Hannisdal E, et al. Second malignancies after treatment of Hodgkin’s disease: the influence of treatment, follow-up and age.J Clin Oncol. 1993;11:255–261.
Neglia J, Shapiro R, Haake R, et al. Second neoplasms following bone marrow transplantation [abstract].Blood. 1992;80(suppl 1):169a.
Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.J Clin Oncol. 1994;12:2527–2534.
Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin’s lymphoma.J Clin Oncol. 1994;12:2535–2542.
Heim S. Cytogenetic findings in primary and secondary MDS.Leuk Res. 1992;16:43–46.
Pedersen-Bjergaard J, Anderson MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation.Blood. 2000;95:3273–3279.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kobayashi, R., Arioka, H., Yoshida, M. et al. Prolonged Bone Marrow Failure With Monosomy 7 After Engraftment Failure Following Bone Marrow Transplantation. Int J Hematol 73, 258–261 (2001). https://doi.org/10.1007/BF02981947
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02981947